Delving into the Latest Updates on LH-025 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Target

NF-κB

Mechanism

NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors)

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Colitis, Ulcerative

Originator Organization

Dr. August Wolff GmbH & Co. KG Arzneimittel

Active Organization-

Inactive Organization

Link Health Group Ltd.

Shenzhen JYMed Technology Co., Ltd.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估醋酸来普舒肽口服冻干粉治疗活动期轻度溃疡性结肠炎的耐受性和安全性次要目的：考察LH025在活动期轻度溃疡性结肠炎患者中的药代动力学特征；研究LH025治疗活动期轻度溃疡性结肠炎患者的有效性探索目的：探索LH025在活动期轻度溃疡性结肠炎患者中的药代动力学指标和药效学指标的关系

[Translation]

Primary objective: To evaluate the tolerability and safety of lepsulotide acetate oral lyophilized powder in the treatment of active mild ulcerative colitis Secondary objective: To investigate the pharmacokinetic characteristics of LH025 in patients with active mild ulcerative colitis; To study the effectiveness of LH025 in the treatment of patients with active mild ulcerative colitis Exploratory objective: To explore the relationship between the pharmacokinetic and pharmacodynamic indicators of LH025 in patients with active mild ulcerative colitis

Start Date-

Sponsor / Collaborator

Shenzhen JYMed Technology Co., Ltd.

[+1]

100 Clinical Results associated with LH-025

Login to view more data

100 Translational Medicine associated with LH-025

Login to view more data

100 Patents (Medical) associated with LH-025

Login to view more data

100 Deals associated with LH-025

Login to view more data